The inadequate and/or insufficient safety and tolerability profile of 'typical' AD therapies produce familiar social and economic difficulties.
17 Because of insufficient safety and tolerability data for artesunate-mefloquine, there has been concern regarding the use of this combination in African children, which restricted its deployment in this setting.
This study was implemented to assess the efficacy and safety of once-daily quetiapine XR in schizophrenic patients with switched from other antipsychotics which were suboptimal due to insufficient efficacy or tolerability.
The subjects had a score of 4 (moderate) or greater on any of the 7 items of the Positive and Negative Syndrome Scale (PANSS) Positive Symptom Subscale and needed to switch from previous antipsychotics due to insufficient efficacy or tolerability (intolerable adverse events reported by the patient or observed by the principal investigator).
As this outcome variable is dependent on the number of treatment discontinuations, which mainly occur for insufficient efficacy and tolerability issues, it indicates that the overall efficacy and safety of lumiracoxib 100 mg o.d. is comparable with that of celecoxib 200 mg o.d.
– Despite the appeal of switching antipsychotics, there are also potential concerns of complications from attempting a switch, such as symptom exacerbation, insufficient efficacy, and new tolerability problems emerging from the "post-switch" medication.
As discontinuations can occur due to insufficient efficacy and/or safety or tolerability issues, retention of patients on treatment provides a measure of the overall effectiveness of the treatment.
Eligible subjects were adults with clinically stable, Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV defined schizophrenia or schizoaffective DSM-IV definedre conschizophreniapriate candidates for schizoaffectivetheir current antipsychotic medisorders (due to insufficient efficacy and/or safety or tolerability concerns).
Treatment-naive patients or patients unsatisfied with pre-treatment due to insufficient control of drug-seeking and/or tolerability were also excluded.
In the case of adalimumab and infliximab, respondents cited a number of reasons not to prescribe these treatments, including cost, insufficient long-term data, concerns with safety and tolerability, and difficulty of administration.
